As Chief Financial Officer, Jen Wilson oversees the financial wellness of VMS BioMarketing to ensure upward-trending growth. She joined the company in May 2021 bringing a relentless passion to improve the way healthcare is delivered and provided to patients.

Prior to working at VMS, Jen was Vice President of Business Development at TherapeuticsMD, a biotech company whose mission is to empower women with innovative solutions that help them transition through meaningful stages of life. She was primarily responsible for maximizing the value of the company's assets through corporate transactions such as the ambitious move into contraception with the acquisition of exclusive rights to ANNOVERA, growing the company’s product portfolio into one of the largest therapeutic categories in pharma. She was also instrumental in bringing the company’s innovative menopause products to women outside of the U.S. and across the world by executing a world-wide out-licensing transaction for the company’s menopause franchise.

Jen started her career in investment banking, working in the Bank of America Merrill Lynch healthcare group. Innovation across life sciences and healthcare services allowed her to work on transformational transactions for companies such as Valeant Pharmaceuticals, Cardinal Health, and Iasis Healthcare. From investment banking she then moved to the payer market, working for Anthem where was she was involved in hallmark acquisitions such as Amerigroup, Cigna, 1-800 Contacts, and American Well. At Anthem, she grew her M&A experience leading strategic transactions totaling over $78 billion.

In 2019, Jen was honored in the 16th Annual Stevie® Awards for Women in Business as a finalist for Female Executive of the Year. She earned her Bachelor of Science degree in business finance from Indiana University.